UNSPSC 51162023: Ephedrine/hydroxyzine/theophylline

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162023 Ephedrine/hydroxyzine/theophylline is a Commodity code that does not match the work actually being solicited under it in recent state and local procurement. The code nominally describes specific pharmaceutical compounds, yet recent opportunities tagged to this code show state and local governments procuring naloxone and drug deactivation systems, on-site pharmacy services, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing, and direct-to-manufacturer prescription program capabilities — none of which are ephedrine, hydroxyzine, or theophylline. The issuing bodies span county health departments (Seminole County, Florida; Hall County, Georgia), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across multiple states including Oregon). The geographic spread includes Florida, Georgia, Texas, Minnesota, and Oregon based on posted opportunities from June and May 2026.

Representative recent solicitations illustrate the mismatch. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response date and quarterly deliveries to the Seminole County Community Health Building. Hall County, Georgia issued RFQ/P #47-010 in May 2026 for a single on-site pharmacy services provider to deliver comprehensive pharmacy services to approximately 3,005 eligible individuals, with a June 4, 2026 response deadline and a one-year contract term beginning January 1, 2027. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP for generic multi-source pharmaceuticals and over-the-counter products through authorized wholesalers, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 to gather vendor information about direct-to-manufacturer prescription programs. The code shows little relevant recent activity aligned with its nominal pharmaceutical scope.